

Esc2 orchestrates substrate-specific sumoylation by acting as a SUMO E2 cofactor in genome maintenance

Shibai Li,^{1,5} Jacob N. Bonner,^{1,2,5,6} Bingbing Wan,^{1,7} Stephen So,³ Ashley Summers,⁴ Leticia Gonzalez,³ Xiaoyu Xue,^{3,4} and Xiaolan Zhao^{1,2}

¹Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA; ²Program in Biochemistry, Cell, and Molecular Biology, Weill Cornell Graduate School of Medical Sciences, New York, New York 10065, USA; ³Department of Chemistry and Biochemistry, Texas State University, San Marcos, Texas 78666, USA; ⁴Materials Science, Engineering, and Commercialization Program, Texas State University, San Marcos, Texas 78666, USA

SUMO modification regulates diverse cellular processes by targeting hundreds of proteins. However, the limited number of sumoylation enzymes raises the question of how such a large number of substrates are efficiently modified. Specifically, how genome maintenance factors are dynamically sumoylated at DNA replication and repair sites to modulate their functions is poorly understood. Here, we demonstrate a role for the conserved yeast Esc2 protein in this process by acting as a SUMO E2 cofactor. Esc2 is required for genome stability and binds to Holliday junctions and replication fork structures. Our targeted screen found that Esc2 promotes the sumoylation of a Holliday junction dissolution complex and specific replisome proteins. Esc2 does not elicit these effects via stable interactions with substrates or their common SUMO E3. Rather, we show that a SUMO-like domain of Esc2 stimulates sumoylation by exploiting a noncovalent SUMO binding site on the E2 enzyme. This role of Esc2 in sumoylation is required for Holliday junction clearance and genome stability. Our findings thus suggest that Esc2 acts as a SUMO E2 cofactor at distinct DNA structures to promote the sumoylation of specific substrates and genome maintenance.

[*Keywords:* Esc2; homologous recombination; SUMO E2; genome maintenance]

Supplemental material is available for this article.

Received September 11, 2020; revised version accepted December 10, 2020.

SUMO (small ubiquitin-like modifier) regulates many cellular processes via covalent modification of a myriad of proteins. Substrate sumoylation requires the sequential action of the trio of SUMO E1, E2, and E3 enzymes, akin to ubiquitination. However, unlike the vast array of ubiquitination enzymes, all organisms examined so far contain only a single SUMO E1 and E2 enzyme and a few SUMO E3s (Pichler et al. 2017). For example, in budding yeast, the Aos1-Uba2 heterodimeric E1, the Ubc9 E2, and three mitotic E3s (Siz1, Siz2, and Mms21) are responsible for sumoylating hundreds of proteins (Albuquerque et al. 2013). How a large number of proteins are specifically and efficiently modified by a small number of sumoylation enzymes is an outstanding question. Because SUMO is directly transferred from the Ubc9 E2 active site to substrates with the help of E3s, efficient

modification of large numbers of diverse substrates may require cofactors to direct E2 and E3 functions in a spatially or temporally regulated manner. Addressing this possibility could provide new insights into sumoylation mechanisms and regulation.

Here, we investigated the conserved genome stability factor Esc2 in budding yeast and its roles in DNA damage-induced sumoylation (Cremona et al. 2012; Psakhye and Jentsch 2012). The Esc2 family of proteins has been implicated in sumoylation; however, a unified mechanism of their functions has yet to be established. While the fission yeast Esc2 ortholog, Rad60, has been proposed as a general regulator of the Nse2 SUMO E3 (Mms21 ortholog) (Prudden et al. 2011), studies in budding yeast reveal a more complex scenario. Both Esc2 and Mms21 support Holliday junction (HJ) clearance in response to DNA damage (Zhao and Blobel 2005; Branzei et al. 2006; Mankouri et al. 2009; Sollier et al. 2009; Choi et al. 2010),

⁵These authors contributed equally to this work.

Present addresses: ⁵Department of Molecular and Cellular Biology, University of California at Davis, Davis, CA 95616, USA; ⁷Key Laboratory of Systems Biomedicine, Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, Shanghai 200240, China.

Corresponding authors: zhaox1@msskcc.org, xiaoyu.xue@txstate.edu
Article published online ahead of print. Article and publication date are online at <http://www.genesdev.org/cgi/doi/10.1101/gad.344739.120>.

© 2021 Li et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genesdev.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

but they were reported to affect different pathways: Mms21 promotes the sumoylation of the HJ dissolution enzyme, the Sgs1-Top3-Rmi1 complex (STR), whereas Esc2 stimulates a HJ clearance pathway mediated by the Mus81-Mms4 nuclease (Bermúdez-López et al. 2016; Bonner et al. 2016; Sebesta et al. 2017). The effect of Esc2 on the Mus81-Mms4 pathway depends on its DNA binding domain that has a strong preference for HJ and replication fork structures (Urulangi et al. 2015; Sebesta et al. 2017). Distinct from Esc2, the Smc5/6 complex, of which Mms21 is an obligate subunit, localizes across chromosomes and affects sumoylation at a variety of DNA structures (Zhao and Blobel 2005; Lindroos et al. 2006; Takahashi et al. 2008; Bermúdez-López et al. 2016; Bonner et al. 2016; Meng et al. 2019; Winczura et al. 2019; Whalen et al. 2020). The differences described above raise the question of whether Esc2 influences sumoylation as a general regulator of the Mms21 E3 or through other mechanism(s).

Interestingly, the Esc2 family of proteins possesses two SUMO-like domains (SLD1 and SLD2), and SLD2 can bind to the Ubc9 SUMO E2 (Novatchkova et al. 2005; Prudden et al. 2009; Sollier et al. 2009; Sekiyama et al. 2010). These common features suggest a potential role for these proteins in assisting Ubc9. In this work, we tested this possibility and clarified the functional link between Esc2 and Mms21. Our targeted screen of genome stability factors reveals that Esc2 specifically influences the Mms21 substrates associating with HJs or replication fork structures. Our complementary in vivo and in vitro tests demonstrate that the role of Esc2 in sumoylation is mediated by its SLD2 binding to the so-called “backside” of Ubc9. We show that this binding contributes to HJ clearance and genome stability in cells. Our work thus uncovers Esc2 as a SUMO E2 cofactor that aids the sumoylation of Mms21 substrates located at HJs and replication forks to enhance repair completion and preserve genome integrity.

Results

Esc2 promotes the sumoylation of a subset of Mms21 substrates

To elucidate the role(s) of Esc2 in sumoylation and its relationship with the Mms21 E3, we queried how Esc2 loss influences DNA damage-induced sumoylation of genome maintenance factors. Given that both *esc2* and *mms21* mutants accumulate HJ structures upon MMS treatment that are resolved by the STR complex (Branzei et al. 2006; Mankouri et al. 2009; Sollier et al. 2009), we first examined STR sumoylation. Mms21-mediated STR sumoylation is thought to occur at HJs and contribute to HJ clearance (Bermúdez-López et al. 2016; Bonner et al. 2016). We found that in *esc2Δ* cells, all three STR subunits had reduced sumoylation levels upon MMS treatment (Fig. 1A), suggesting that this defect could underlie the elevated HJ levels in *esc2Δ* cells in this condition.

Since Esc2 preferentially binds to HJs and replication fork structures (Urulangi et al. 2015; Sebesta et al. 2017), we next examined two replisome proteins whose

sumoylation is regulated by Mms21. Monosumoylation of the leading strand DNA polymerase Pol2, which was suggested to occur at replication forks, and the disumoylated form of the Mcm3 subunit of the replicative helicase are largely abolished in *mms21* E3 mutants (Albuquerque et al. 2016; Meng et al. 2019; Winczura et al. 2019). We found that *esc2Δ* phenocopied the *mms21* mutant in both cases (Fig. 1B). In contrast, *esc2Δ* cells were proficient for the sumoylation of Mms21 substrates located at other types of DNA structures (Fig. 1C,D). These include the dsDNA end binding protein Yku70, ssDNA binding protein Rfa1, and subunits of three SMC complexes that predominantly associate with dsDNA (Zhao and Blobel 2005; Takahashi et al. 2008; Whalen et al. 2020). In addition, *esc2Δ* cells maintained the sumoylation of Siz E3 substrates that bind to HJ, replication fork, or DNA flap structures (Supplemental Fig. S1A–C; Hoege et al. 2002; Stelter and Ulrich 2003; Sarangi et al. 2014; Talhaoui et al. 2018). Our data (summarized in Fig. 1E) suggest that, while Esc2 has a functional partnership with Mms21, it does not act as a general regulator of this E3; rather, Esc2 specifically contributes to the sumoylation of Mms21 substrates associating with HJs and replication fork structures.

Query of Esc2 interactions with SUMO E2, SUMO E3, SUMO, and SUMO substrates

Consistent with the above notion that Esc2 is not a general Mms21 regulator, we did not detect association of Esc2 with the Smc5/6 complex, of which Mms21 is an obligate subunit, either through coimmunoprecipitation or yeast two-hybrid assays (Fig. 2A,B). We also did not find evidence that Esc2 could bind to the SUMO substrates identified above or bridge their interactions with Mms21. Yeast two-hybrid tests did not reveal interaction of Esc2 with STR subunits, Pol2, or Mcm3 (Fig. 2B). Moreover, Esc2 did not coimmunoprecipitate with Sgs1 or Pol2, whereas the association of Sgs1 with Smc5 or Pol2 with its partner protein Dpb2 was detected (Fig. 2A,C; Supplemental Fig. S2A). Purified Esc2 did not show interaction with STR or Smc5/6 in vitro (Supplemental Fig. S2B,C). Finally, Esc2 loss did not affect Smc5 association with Sgs1 or Pol2 in vivo (Fig. 2D; Supplemental Fig. S2D).

As Esc2 has been previously shown to interact with Ubc9 and SUMO by yeast two-hybrid assay (Sollier et al. 2009), we explored the possibility that Esc2 elicits its effects via these interactions. We found that Esc2 interacted with Ubc9 and weakly with SUMO (Smt3) in yeast two-hybrid assays (Fig. 2B). To discern direct binding from indirect association, we performed in vitro pull-down tests using purified proteins. While Esc2 interaction with Ubc9 was readily detected, we failed to detect Esc2 interaction with either the monomeric SUMO or a four-SUMO fusion construct, which can enhance SUMO-mediated interactions (Fig. 2E,F). Using microscale thermophoresis, we found that Ubc9 bound to Esc2 with a dissociation constant K_d of 372 ± 57 nM (Supplemental Fig. S2E). Taken together, the above results suggest that Esc2 can associate with the SUMO E2, which may contribute to its sumoylation function.




Figure 1. Esc2 promotes the sumoylation of a specific set of Mms21 substrates. (A) Sumoylation levels of the subunits of the Sgs1-Top3-Rmi1 complex are reduced in *esc2Δ* cells. Cells containing His8-tagged SUMO were treated with 0.03% MMS for 2 h to induce STR sumoylation. Sumoylated proteins were isolated using Ni-NTA resins and examined by immunoblotting using antibodies recognizing the tag fused to the endogenous Sgs1, Top3, or Rmi1 to visualize sumoylated forms of the proteins (-S), which are indicated by lines next to the blots. Loading is shown by Ponceau S stain (stain). (WT) Wild type. Similar methods for examining sumoylation and annotation of immunoblots are used in subsequent panels unless otherwise noted. (B) *esc2Δ* reduces the levels of mono-sumoylated form of Pol2 and di-sumoylated form of Mcm3. (Left) HA-tagged Pol2 was immunoprecipitated and its sumoylated form was detected by immunoblotting using anti-SUMO antibody as shown previously (Meng et al. 2019). The unmodified band was detected against the tag (HA) for equal loading control. (Right) Mcm3 sumoylation was examined as in A. (C) *esc2Δ* cells maintain the sumoylation levels of Yku70 and Rfa1. Yku70 sumoylation was examined as in B (left) and as shown previously (Zhao and Blobel 2005), whereas Rfa1 sumoylation was examined as in A as shown previously (Chung and Zhao 2015). (D) *esc2Δ* cells maintain the sumoylation levels for the subunits of three SMC complexes, namely cohesin, condensin, and the Smc5/6 complex. Sumoylation of Smc2 was examined as in B (left), and sumoylation of the other proteins was examined as in A. (E) Summary of the effects of *esc2Δ* on Mms21-dependent sumoylation of DNA metabolism proteins. Results in A–D show that *esc2Δ* reduces the sumoylation of proteins known to associate with HJ and replication fork structures but not those that mainly interact with ssDNA or dsDNA.

SLD2 binding to Ubc9 is critical for Esc2-mediated sumoylation

Esc2 family proteins contain two SUMO-like domains, SLD1 and SLD2 (Novatchkova et al. 2005). In Esc2, these domains are located C-terminal from the DNA binding domain (Fig. 3A). SLD2 has a higher degree of sequence similarity with SUMO than SLD1 and adopts a structural fold reminiscent of SUMO; however, SLD2 lacks key features required for conjugation (Prudden et al. 2009; Sekiyama et al. 2010). Structural studies show that SLD2 of the fission yeast Rad60 and the mouse Nip45 proteins bind to Ubc9 in a similar fashion as SUMO (Sekiyama et al. 2010; Prudden et al. 2011). Both SLD2 and SUMO bind to the “Ubc9 ‘backside,’” which is opposite from the Ubc9 active site that forms a thioester bond with SUMO (Supplemental Fig. S3A). While SUMO binding to the Ubc9 backside can stimulate SUMO chain formation (Knipscheer et al. 2007), it is unclear how the association of SLD2 with Ubc9 affects substrate sumoylation in cells.

To elucidate how SLD2 binding to Ubc9 contributes to Esc2 functions, we aimed to generate a mutant disrupting this interaction. We first built a structural model of the

SLD2-Ubc9 complex using homology modeling based on the published structures of budding yeast Ubc9 and the complex of Ubc9-Rad60^{SLD2} (Duda et al. 2007; Sekiyama et al. 2010; Prudden et al. 2011). This model highlighted the conserved D449 residue of SLD2 at the Ubc9 interface (Supplemental Fig. S3B). We mutated D449 and the adjacent conserved residue D447 to alanine (D447A, D449A), generating the previously described *esc2-SLD2m* mutant that has only been examined in combination with a SLD1 mutant (D286A, I287Y or *-SLD1m*) (Uru-langodi et al. 2015). We found that *esc2-SLD2m*, but not *esc2-SLD1m*, abrogated the interaction with Ubc9 in a yeast two-hybrid assay (Fig. 3B). In vitro pull-down tests using purified proteins validated the two-hybrid result (Fig. 3C; Supplemental Fig. S3C). Additionally, the Esc2-SLD2m mutant protein and the wild-type Esc2 protein showed similar circular dichroism profiles, indicating that the loss of interaction was not due to altered conformation of the mutant protein (Supplemental Fig. S3D). Taken together, we conclude that SLD2, but not SLD1, is responsible for the Esc2-Ubc9 interaction, and *esc2-SLD2m* effectively disrupts this interaction.

We then used *esc2-SLD2m* to evaluate the biological significance of the Esc2-Ubc9 interaction. Strikingly,




Figure 2. Examination of Esc2 interactions with Ubc9, SUMO, STR, and the Smc5/6 complex. (A) Smc5 coimmunoprecipitates with Sgs1 but not Esc2. Cells containing endogenously Myc-tagged Esc2 and HA-tagged Sgs1, with or without TAP-tagged Smc5, were examined by co-IP tests. Representative immunoblots examining co-IP eluate (IP) and the whole cell extract (WCE) are shown. (B) Esc2 interacts with Ubc9 and SUMO (Smt3), but not subunits of the Smc5/6 complex and the STR complex nor Pol2 and Mcm3 in yeast-two-hybrid assays. (AD) Gal4 activation domain, (BD) Gal4 DNA binding domain, (vec) vector. SC-Leu-Trp media (-L-T) select for BD and AD plasmids, while SC-Leu-Trp-Ade media (L-T-A) report for positive interactions. (C) Esc2 does not coimmunoprecipitate with Sgs1. Similar levels of Sgs1 were detected in IP samples regardless of whether cells contain Myc-tagged Esc2 or not, reflecting nonspecific binding of Sgs1 to the beads. (D) Smc5 copurifies with Sgs1 regardless of the Esc2 status. Experiments were done as in A. (E,F) Protein binding assays showing that Esc2 binds to Ubc9 but not SUMO or a SUMO chain. Purified GST or GST-Esc2 proteins bound to glutathione beads were examined for their abilities to pull down Ubc9 (E), SUMO (F, lanes 1–6), or SUMO chain composed of four tandem SUMO moieties (F, lanes 7–12). Proteins were examined by SDS-PAGE, and pictures of representative gels after Coomassie blue stain are shown. (S) Supernatant, (W) wash, (E) eluate.

esc2-SLD2m, which supported wild-type protein levels, behaved like *esc2Δ* in reducing the sumoylation levels of STR subunits in cells, while *esc2-SLD1m* had no effect (Fig. 3D; Supplemental Fig. S3E). In addition, *esc2-SLD2m* abolished Pol2 monosumoylation and Mcm3 disumoylation, whereas *esc2-SLD1m* showed milder defects (Fig. 3E). We suspect that SLD1 involvement in replication fork regulation (Urulangodi et al. 2015) and/or the compromised expression of the Esc2-SLD1m protein (Supplemental Fig. S3E) could explain the SLD1 mutant's effect on Pol2 and Mcm3 sumoylation. Collectively, our results indicate that Esc2 uses its SLD2 interaction with Ubc9 to promote substrate sumoylation in cells.

In vitro Sgs1 and Top3 sumoylation systems recapitulate *in vivo* requirements

To discern whether SLD2 can directly influence the sumoylation reaction, we established an *in vitro* sumoylation system for Sgs1 using purified proteins (Supplemental Figs. S2B, S3F). Incubation of Sgs1 with SUMO, the SUMO E1, the Ubc9 E2, and ATP produced high molecular weight Sgs1 species reminiscent of the endogenous Sgs1 sumoyla-

tion forms (Supplemental Fig. S3G; Bermúdez-López et al. 2016; Bonner et al. 2016). To confirm that these species were indeed sumoylated forms of Sgs1, we purified two Sgs1 variants known to be defective in sumoylation *in vivo*, namely Sgs1-K621R mutated for the main sumoylation site and Sgs1-sim mutated for its SUMO interacting motifs (Supplemental Fig. S3F; Bermúdez-López et al. 2016; Bonner et al. 2016). As expected, these variants were not sumoylated in the *in vitro* reactions, validating our *in vitro* system (Supplemental Fig. S3G).

Next, we purified the Mms21-Smc5 complex as the SUMO E3 complex, because Mms21 is not well expressed on its own (Supplemental Fig. S3F; Zhao and Blobel 2005). The addition of the Mms21-Smc5 SUMO E3 complex into the sumoylation reactions containing the STR complex greatly stimulated Sgs1 and Top3 sumoylation over time, as evidenced by their upshifted bands on immunoblots (Fig. 4A). This is in line with *in vivo* findings (Bermúdez-López et al. 2016; Bonner et al. 2016), demonstrating that Mms21 directly enhances Sgs1 and Top3 sumoylation. Rmi1 was not sumoylated in this system, possibly because its sumoylation requires additional factors not present in the assay. We focused on Sgs1 and Top3 sumoylation thereafter.




Figure 3. Esc2 binding to Ubc9 is required for efficient sumoylation of the STR complex, Pol2 and Mcm3. (A) A schematic of Esc2 protein domains. (DNA) DNA-binding domain that prefers to bind HJ and fork structures, (SLD1) SUMO-like domain 1, (SLD2) SUMO-like domain 2. (B) Mutating the SLD2 but not SLD1 domain of Esc2 abolishes its interaction with Ubc9 in yeast two-hybrid assays. Experiments were done and data are presented as in Figure 2B. (C) Esc2-SLD2m abolished Ubc9 interaction in vitro. Experiments were done and data are presented as in Figure 2E. Dotted line denotes removal of superfluous lanes. (D) *esc2-SLD2m*, but not *-SLD1m*, reduces sumoylation levels of the STR subunits in cells. Experiments were done and data are presented as in Figure 1A. (E) *esc2-SLD2m* reduces levels of monosumoylation of Pol2 and disumoylation of Mcm3 in vivo. Experiments were done and data are presented as in Figure 1B.

Esc2 stimulates Sgs1 and Top3 sumoylation and this requires SLD2 binding to Ubc9

We proceeded to test whether Esc2 directly stimulated Sgs1 and Top3 sumoylation. As in vitro sumoylation reactions require high concentrations of SUMO, we first asked whether SUMO and Esc2 compete for binding to Ubc9, which could obscure potential effects of Esc2 in the assay. Indeed, we found that Ubc9 prebound to GST-Esc2 on beads was competed off with increased levels of SUMO (Supplemental Fig. S4A). To circumvent this competition, we used a SUMO variant mutated in a key residue for binding to the Ubc9 backside, Smt3-D68R (SUMO-DR) (Duda et al. 2007; Knipscheer et al. 2007). SUMO-DR failed to compete with Esc2 for Ubc9 binding as expected (Supplemental Fig. S4B). Importantly, SUMO-DR showed wild-type competency in conjugating to Ubc9 in the presence of SUMO E1 and ATP (Supplemental Fig. S4C), indicating that it transfers proficiently from E1 to E2. Furthermore, when used in the Sgs1-Top3 sumoylation assay described above, SUMO-DR supported the sumoylation of both proteins (Fig. 4A). In these reactions, SUMO-DR gave rise to fewer sumoylated species than SUMO, particularly those of higher molecular weights, consistent with its reported impairment in SUMO chain formation (Fig. 4A; Duda et al. 2007; Knipscheer et al. 2007). Taken together, the above results validate the use of SUMO-DR in the in vitro sumoylation system.

We moved on to examine how Esc2 affected in vitro sumoylation using SUMO-DR. Esc2 did not affect E1-mediated SUMO conjugation of Ubc9 (Supplemental Fig.

S4C), suggesting that Esc2 must regulate Ubc9 after it is conjugated (charged) with SUMO at its active site. Time course experiments showed that Esc2 stimulated E3-dependent sumoylation of Sgs1 and, to a lesser degree, Top3 (Fig. 4B). For instance, while a small proportion of Sgs1 was sumoylated in the absence of Esc2 in 5 min (Fig. 4B, lane 3, top), the majority of Sgs1 was sumoylated in the presence of Esc2 in the same time (Fig. 4B, lane 7, top). Importantly, the Esc2-SLD2m mutant that does not interact with Ubc9 failed to elicit the same effect, indicating that Esc2 stimulation of sumoylation hinges upon its SLD2-mediated interaction with Ubc9 (Fig. 4B). Thus, our in vivo and in vitro results demonstrate a direct role for Esc2 and its SLD2 in stimulating substrate sumoylation.

The structural mimicry of SLD2 underlies its stimulation of STR sumoylation

In addressing the mechanisms by which SLD2 binding to Ubc9 stimulates substrate sumoylation, we considered previous findings that SUMO binding to the Ubc9 backside better orients the Ubc9 active site for SUMO transfer in SUMO chain formation (Duda et al. 2007; Knipscheer et al. 2007). We tested whether SLD2 promoted substrate sumoylation via a similar structure-based mechanism by examining whether SUMO could substitute for SLD2. To this end, we generated and purified an Esc2 variant wherein its SLD2 was replaced by a SUMO moiety that lacked the diglycine motif required for conjugation (Fig. 4C).




Figure 4. Esc2 aids sumoylation via its SLD2 binding to the Ubc9 backside. (A) Mms21-Smc5 stimulates Sgs1 and Top3 sumoylation in the presence of SUMO or SUMO-D68R. In vitro sumoylation assays were performed by incubating purified STR complex with the SUMO E1, the SUMO E2, SUMO (or SUMO-DR), and ATP in the presence or absence of the Mms21-Smc5 SUMO E3 at 30°C for the indicated time (for details, see the Materials and methods). Sgs1 tagged with FLAG and Top3 tagged with CBP and their sumoylated forms were detected by immunoblotting against the tags fused to them. Asterisk indicates a cross-reaction band. (B) Esc2, but not Esc2-SLD2m, stimulates Sgs1 and Top3 sumoylation in vitro. Sumoylation assays were performed as in panel A in the presence of Mms21-Smc5 and SUMO-DR, except Top3 is tagged with V5. The inclusion of Esc2 or Esc2-SLD2m is indicated. (C) Schematics of two Esc2 variants wherein its SLD2 is replaced by SUMO (Esc2-SLD2Δ-Su) or by SUMO-D68R (Esc2-SLD2Δ-SuDR). (D) Esc2-SLD2Δ-Su, but not esc2-SLD2Δ-SuDR, protein interacts with Ubc9 in vitro. GST pull-down tests were performed and results are presented as in Figure 2E. (E) SUMO, but not SUMO-DR, can replace the SLD2 of Esc2 in stimulating Sgs1 and Top3 sumoylation. Sumoylation assays were performed as in A in the presence of Mms21-Smc5 and SUMO-DR, except with shorter time courses. (F) SLD2 can be replaced by SUMO, but not SUMO-DR, to support STR sumoylation in cells. Experiments were done and data are presented as in Figure 1A.

The resulting Esc2-SLD2Δ-Su fusion protein was proficient for interaction with Ubc9 (Fig. 4D; Supplemental Fig. S3C). Significantly, Esc2-SLD2Δ-Su stimulated in vitro Sgs1 and Top3 sumoylation to a similar extent as Esc2 (Fig. 4E). Moreover, this effect relied on binding to Ubc9, since the Esc2-SLD2Δ-SuDR variant containing the D68R mutation that impairs Ubc9 backside interaction could not stimulate substrate sumoylation (Fig. 4C–E). These results indicate that SLD2 exploits the SUMO binding surface on the Ubc9 backside to enhance the SUMO E2 function. We note that, unlike SUMO, Esc2 did not stimulate free SUMO chain formation, suggesting that, despite using a similar strategy for associating with the E2, SUMO and Esc2 exhibit distinct effects (Supplemental Fig. S4D).

To extend our in vitro findings, we replaced the *ESC2* gene at its endogenous locus in cells with either *esc2-SLD2Δ-Su* or *esc2-SLD2Δ-SuDR*. While *esc2-SLD2Δ-Su* maintained wild-type sumoylation levels of STR subunits, *esc2-SLD2Δ-SuDR* was defective, as seen for *esc2-SLD2m* (Fig. 4F). Thus, complementary in vitro and in vivo data support the conclusion that SLD2 exploits the SUMO binding surface of Ubc9 to enhance substrate sumoylation.

Esc2 binding to Ubc9 limits GCRs and recombination intermediate accumulation

We next addressed the impact of the Esc2-Ubc9 interaction on genome maintenance. Esc2 is known to promote

genome stability during growth and enhance HJ removal in the presence of MMS (Sollier et al. 2009; Albuquerque et al. 2013). We first queried genome stability using the gross chromosomal rearrangement (GCR) assay (Putnam et al. 2009). Similar to previous reports, *esc2Δ* cells exhibited a 23-fold increase in GCR rates compared with wild-type cells (Kanellis et al. 2007; Mankouri et al. 2009). We found that *esc2-SLD2m* cells showed an approximately threefold higher GCR rate than wild type (Fig. 5A), indicating that the Esc2-Ubc9 association contributes to Esc2's roles in maintaining genome stability.

Next, we evaluated the impact of the Esc2-Ubc9 interaction on HJ removal. We used both genetic assays and 2D agarose gel electrophoresis followed by Southern blotting (2D gel) for detecting X-shaped molecules (X-mols) such as HJ structures (Fig. 5B, left). When cells replicated in MMS, *esc2-SLD2m* cells exhibited a two- to threefold increase in the levels of X-mols compared with wild type at loci near ARS315 or ARS1212 (Fig. 5B, middle and right). This defect likely reflects an impairment in STR-mediated HJ clearance and not the Mus81-Mms4 nuclease function, since STR is responsible for X-mol removal when cells grow in the presence of MMS (Liberi et al. 2005; Matos et al. 2011; Sebesta et al. 2017). In addition, we found that Esc2-SLD2m was proficient for Mus81-

Mms4 association (Supplemental Fig. S5A). Furthermore, like STR mutants, *esc2-SLD2m* sensitized cells lacking Mms4 or Slx4, which acts in other HJ removal pathways (Fig. 5C,D). In both cases, *esc2-SLD2m* rendered these mutant cells more sensitive to MMS (Fig. 5D). In the case of *slx4Δ*, the double mutants also exhibited slower growth on dissection plates (Fig. 5C). As the sensitization effect of *esc2-SLD2m* toward *mms4Δ* or *slx4Δ* cells was less severe than *esc2Δ*, Esc2 must have SLD2-independent roles. Interestingly, we found that *esc2-SLD2Δ-Su* did not sensitize *mms4Δ* or *slx4Δ*, while *esc2-SLD2Δ-SuDR* did, suggesting that the observed sensitization by *esc2* mutants stems from the loss of Esc2-Ubc9 interaction (Supplemental Fig. S5B,C). In summary, the corroborative data described above suggest that the Esc2-Ubc9 interaction limits recombination intermediate accumulation in cells, and this can be partly mediated by regulating STR sumoylation.

Discussion

Protein sumoylation regulates many cellular processes, yet it remains unclear how the limited number of sumoylation enzymes can efficiently modify hundreds of diverse




Figure 5. Esc2 binding to Ubc9 curbs levels of GCR and recombination intermediates. (A) *esc2Δ* and *esc2-SLD2m* mutants increase GCR rates. For each genotype, the median rate of at least nine cultures was calculated from two biological duplicates. Error bars are 95% confidence intervals. Two-tailed Mann-Whitney tests were performed for statistical analysis. (B) 2D gel data show that *esc2-SLD2m* mutants increase X-mol levels at two genomic sites. α -Factor-arrested G1 cells were released into media containing MMS for 2 h. Samples were examined by 2D gel followed by Southern blotting using probes at ARS315 or ARS1212. (Left) A schematic of 2D gel images with X-mol spike indicated by red arrowhead. (Middle) Representative 2D gel images. (Right) Quantification of relative X-mol levels from two different spore clones per genotype, with error bars representing standard deviations. WT level was set to 1.0, and the P -value is derived by Student's t -test. (C) Tetrad analyses from diploid strains with indicated genotype. Spore clones were grown for 2 d at 30°C. Spores containing different mutations are identified based on genotyping. One representative tetrad among at least nine tetrads per diploid strain is shown. (D) *esc2-SLD2m* worsens genotoxic sensitivity of *slx4Δ* and *mms4Δ* cells. Cells were spotted in 10-fold serial dilutions and grown for 2 d at 30°C. (E) A model for Esc2 stimulation of specific substrate sumoylation. Esc2 binding to the backside of Ubc9 (SUMO E2) through its SLD2 leads to the stimulation of sumoylation of a subset of Smc5-6-Mms21 E3 substrates, likely at HJ and replication fork sites, contributing to HJ dissolution and genome stability.

substrates within the SUMO proteome. A previous study from the Pichler group showed that sumoylation of the SUMO E2 enzyme leads to increased modification of certain substrates in mammalian cells (Knipscheer et al. 2008). Our work suggests another means wherein an E2 cofactor can enable specific substrate sumoylation in yeast. We show that the conserved Esc2 protein aids the Ubc9 E2 in substrate sumoylation both in vivo and in vitro. Mechanistically, Esc2 uses a SUMO-like domain to bind the Ubc9 backside, stimulating the sumoylation reaction. Genetic and 2D gel results suggest that this role of Esc2 positively affects genome stability and HJ structure elimination.

We found that Esc2 regulated the sumoylation of a subset of Mms21 substrates that associate with HJ and replication fork structures. Previous studies have suggested that STR and Pol2 sumoylation likely occurs at HJ and replication fork structures, respectively (Bonner et al. 2016; Meng et al. 2019). As Esc2 preferentially binds to these DNA structures compared with dsDNA or ssDNA (Urulangodi et al. 2015; Sebesta et al. 2017), Esc2 may be a DNA structure-specific sumoylation regulator.

Our cellular and in vitro data support the conclusion that Esc2 stimulates substrate sumoylation and provide an understanding of the possible mechanisms. Building upon previous findings, we show that the Esc2-Ubc9 interaction depends on its SLD2 rather than SLD1. Our results further suggest that Esc2 likely employs its SLD2 to bind the Ubc9 backside, as seen for its homologs (Prudden et al. 2009; Sekiyama et al. 2010). Importantly, we show for the first time that *esc2-SLD2m* mimics *esc2Δ* in reducing substrate sumoylation in cells. We also established an in vitro system for assaying Sgs1 and Top3 sumoylation in detail. Using this system, we demonstrate that Esc2 directly stimulates the sumoylation reaction in a manner depending on its binding to Ubc9. Significantly, in vitro and in vivo Esc2-dependent sumoylation was supported when SLD2 was replaced by nonconjugatable SUMO, again in a manner requiring its binding to Ubc9. Thus, Esc2 likely uses its SLD2 to exploit a SUMO binding surface on Ubc9 to stimulate E2 function. A noteworthy distinction between SLD2 and SUMO binding to Ubc9 is that the former did not promote free SUMO chain formation; rather, it stimulated substrate sumoylation. Despite this difference, it is possible that Esc2 binding to the Ubc9 backside may also help to orient Ubc9 for transferring SUMO to the substrate lysine residue. This premise is consistent with our observation that Esc2 affects Ubc9 after it is charged with SUMO at its active site.

Molecular details regarding how Esc2 facilitates SUMO transfer from Ubc9 to specific Mms21 substrates is currently unclear. In principle, Esc2 could achieve this effect via binding both to Ubc9 and the Mms21 E3. However, we did not detect a stable interaction between Esc2 and Mms21, though a transient interaction that may elude our detection cannot be excluded. Also, we did not find evidence that Esc2 could stably associate with substrates or bridge substrate-E3 association. Rather, our data suggest that the Esc2-Ubc9 association is crucial for Esc2-mediated sumoylation, at least for the substrates examined here.

It is likely that the association of both Esc2 and Mms21 with HJ and replication fork structures poise them for collaboration at these sites. The specific requirement of Esc2 also suggests that Mms21 action entails distinct features from the Siz E3s. While Siz E3s possess SUMO interaction regions that promote sumoylation (Streich and Lima 2016), Mms21 may use Esc2 to enhance sumoylation. For example, Esc2 binding to Ubc9 during Mms21-mediated sumoylation may better orient the donor SUMO to the target lysine. Alternatively, Esc2 binding to Ubc9 may lead to its own sumoylation, which then allows transient interactions with Mms21 and/or substrates to foster SUMO transfer. Regardless of the mechanism(s), Esc2 collaboration with Mms21 enhances sumoylation events required for HJ and replication fork control during genome stress.

We showed that the impaired sumoylation of STR in *esc2-SLD2m* cells correlated with more X-mols and sensitization of other HJ processing mutants. Thus, the previously documented role of Esc2 in HJ removal during DNA replication (Mankouri et al. 2009; Sollier et al. 2009) can be partly explained by Esc2-mediated STR sumoylation. Although Esc2 can stimulate Mus81-Mms4-mediated HJ cleavage, we show Esc2-SLD2m is proficient for binding to this nuclease. Thus, Esc2 appears to use distinct domains to regulate both STR and the Mus81-Mms4 pathways, likely at different cell cycle stages, thereby acting as a master regulator of HJ removal.

We found that *esc2-SLD2m* had moderately elevated GCR rates. Impairment of multiple sumoylation events likely contributes to this, as a *pol2* sumoylation-defective mutant showed a more subtle GCR increase than *esc2-SLD2m* (Meng et al. 2019). While certain genome instability events, such as HJ accumulation, may not be captured by this GCR assay, the smaller increase in GCRs in *esc2-SLD2m* cells compared with *esc2Δ* cells is consistent with the milder *esc2-SLD2m* phenotype observed in the other assays. These differences likely reflect additional roles of Esc2 in genome regulation, including affecting the DNA helicase Srs2 at replication forks (Urulangodi et al. 2015).

Our data, in conjunction with previous findings, suggest a model wherein Esc2 and Mms21 localized at HJ and replication fork structures collaborate for timely and efficient substrate sumoylation (Fig. 5E). Esc2 binding to the Ubc9 backside can help the SUMO E2 to adopt a productive conformation required for SUMO transfer. Esc2 may also help to target Ubc9 to HJs and replication fork structures to increase the local availability of the enzyme. We note that while SLD2 binding to the Ubc9 backside is a conserved feature of the Esc2 family of proteins (Prudden et al. 2009; Sekiyama et al. 2010), variations of the above model may apply to other organisms. In particular, the fission yeast Rad60 can stably associate with the Nse2 SUMO E3, suggesting broader effects on sumoylation in this organism (Raffa et al. 2006; Prudden et al. 2009). It is also interesting to note that the mammalian Esc2 homolog Nip45 is required for coping with genotoxins, though the underlying mechanisms remain to be understood (Hurov et al. 2010). Elucidating the roles of Esc2 homologs and their SLDs in multicellular organisms will be informative.

In summary, we provide insights into how a conserved SUMO E2 interacting protein stimulates sumoylation during genome maintenance. Our work sets the foundation for future studies on other Ubc9 binding partners to better understand how sumoylation efficiency and specificity can be achieved in a variety of cellular contexts and organisms.

Materials and methods

Yeast strains, plasmids, primers, and genetic procedures

All yeast strains are derivatives of W1588-4C, a *RAD5* derivative of W303 (*MATa ade2-1 can1-100 ura3-1 his3-11,15 leu2-3,112 trp1-1 rad5-535*). At least two strains per genotype were examined in each experiment, and only one is listed in Supplemental Table S1. Standard procedures were used for cell growth, media preparation, epitope tagging at endogenous loci, and spot assays. Plasmids and primers used are listed in Supplemental Tables S2 and S3, respectively. For Figure 5C, at least nine tetrads for each cross were dissected and analyzed, and only one tetrad was shown.

Detection of protein sumoylation in cells

Two methods were used for detecting protein sumoylation according to previous publications. In most cases, sumoylated proteins were pulled down from cells containing His8-tagged SUMO expressed from its endogenous promoter and probed for specific substrates by immunoblotting (Ulrich and Davies 2009; Wei and Zhao 2016). In brief, exponentially growing cells were treated with 0.03% MMS for 2 h before harvest. Protein extracts prepared by 55% TCA were dissolved in buffer A (6 M guanidine HCl, 100 mM sodium phosphate at pH 8.0, 10 mM Tris-HCl at pH 8.0) and incubated overnight with Ni-NTA resin after the addition of 0.05% Tween 20 and 4.4 mM imidazole. Resins were washed twice with buffer A containing 0.05% Tween 20 and four times with buffer C (8 M urea, 100 mM sodium phosphate at pH 6.3, 10 mM Tris-HCl at pH 6.3) containing 0.05% Tween 20. HU buffer (8 M urea, 200 mM Tris-HCl at pH 6.8, 1 mM EDTA, 5% SDS, 0.1% bromophenol blue, 1.5% DTT, 200 mM imidazole) was used to elute proteins to be examined by SDS-PAGE and immunoblotting analyses. Ponceau S stain was used to ensure equal loading.

Epitope-tagged Pol2, Yku70, Smc2, and Saw1 proteins were immunoprecipitated, and their sumoylated forms were detected by an anti-SUMO antibody in immunoblotting analyses (Cremona et al. 2012). In brief, cells were treated as above, and proteins were extracted by RIPA buffer (50 mM Tris-HCl at pH 7.4, 5 mM EDTA, 150 mM NaCl, 1.25% Triton-X 100, 1× protease inhibitor cocktail from Sigma, 40 mM NEM). Immunoprecipitation was carried out by incubating the extracts with sepharose beads conjugated with either IgG recognizing the TAP tag fused to Yku70 and Saw1 or anti-HA antibody for HA-tagged Pol2 and Smc2 at 4°C for 2–6 h. Beads were washed with RIPA containing 0.1% SDS and eluted with protein loading buffer. The unmodified form of the protein, detected by antibody recognizing its corresponding tag in immunoblots, was used for equal loading. Antibodies used included: anti-Myc (Bio X Cell 9E10), anti-TAP (Sigma P1291), anti-HA (Roche 3F10), anti-Rfa1 (a gift from S. Brill), anti-GST (Sigma G7781), anti-SUMO (Zhao and Blobel 2005), anti-PCNA (gift from Helle Ulrich), anti-FLAG (Sigma M2), anti-CBP (Santa Cruz Biotechnology SC33000), anti-V5 (Invitrogen R960-25), anti-Ubc9 (Santa Cruz Biotechnology yN-19 and yC-19), and anti-Dpb2 (gift from H. Araki).

Yeast two-hybrid assay

Standard assay was performed as described previously (Dhingra et al. 2019). Briefly, plasmids containing the Gal4 activation domain (AD) and Gal4 DNA binding domain (BD) with or without the fusion of genes encoding the proteins of interest were transformed in the two-hybrid host strain pJ69-4. The resultant transformants were mixed for each pair of plasmids and spotted on plates containing SC-Trp-Leu (selection of plasmids) and SC-Trp-Leu-Ade (report the expression of the *ADE2* reporter) media. Pictures were taken after plates were incubated for 48 h at 30°C.

Coimmunoprecipitation

Exponentially growing yeast cells were treated with 0.03% MMS for 2 h before harvest. Cells were disrupted by glass bead beating in lysis buffer with Benzonase added to digest nucleic acid before centrifugation for 15 min at 20,000g to obtain whole-cell extract (WCE). The lysis buffer contains 25 mM K-HEPES (pH 7.6), 100 mM NaCl, 100 mM K-glutamate, 5 mM Mg (OAc)₂, 0.02% NP-40, and 0.5% Triton X-100 supplemented by protease inhibitor cocktail (Sigma) and Complete Ultra EDTA-free protease inhibitor (Roche). Proteins of interest were immunoprecipitated using IgG-sepharose beads (for TAP-tagged proteins) or Protein G beads in combination with specific antibodies recognizing the tags on the proteins for 2–4 h at 4°C. Beads were washed five to six times using lysis buffer, and proteins were eluted using loading buffer. After boiling for 5 min, eluted proteins were loaded onto 4%–20% gradient gels (Bio-Rad) and subjected to SDS-PAGE and immunoblotting analyses.

Protein expression and purification

Expression and purification of most recombinant proteins were carried out following previously published protocols. These include FLAG-Sgs1 (Niu et al. 2010), V5-Top3/GST-Rmi1 (Wang et al. 2018), the Mms21/Smc5 complex (Duan et al. 2009), Myc-Smc5/His₆-Strep-Tactin-Smc6 complex (Xue et al. 2014), Esc2 and its variants (Sebesta et al. 2017), Smt3, Smt3-D68R, Ubc9, Aosl-Uba2 (Zhao and Blobel 2005), 4xSmt3 (Gillies et al. 2016), and the Mus81-Mms4 complex (Matulova et al. 2009). Expression and purification of CBP-Top3 and Rmi1 were performed largely as described (Devbhandari et al. 2017). Briefly, yeast cells were lysed in extraction buffer (45 mM Hepes KOH at pH 7.6, 10% glycerol, 0.02% NP40, 300 mM NaCl, 1 mM DTT, 2 mM CaCl₂). Calmodulin affinity resin (Agilent) was incubated with lysate, then washed with washing buffer (45 mM Hepes KOH at pH 7.6, 10% glycerol, 0.02% NP40, 300 mM NaCl, 1 mM DTT, 2 mM CaCl₂) and eluted with elution buffer (45 mM Hepes KOH at pH 7.6, 10% glycerol, 0.02% NP40, 300 mM NaCl, 1 mM DTT, 1 mM EDTA, 2 mM EGTA). The eluate containing CBP-Top3 and Rmi1 complex was diluted with an equal volume of T buffer (25 mM Tris-Cl at pH 7.4, 10% glycerol, 0.5 mM EDTA, 0.01% Igepal, 1 mM DTT) and loaded onto a Resource S column (GE Healthcare). The column was washed with T buffer containing 150 mM KCl and developed with a 25-mL gradient of 150–650 mM KCl. CBP-Top3/Rmi1 was eluted at ~350 mM KCl, and the peak fractions were pooled and concentrated in an Ultracel-10K concentrator (Amicon) before storing at –80°C in aliquots.

In vitro protein binding assays

For GST pull-down assays, 5 µg of GST-tagged Esc2 or its variants was incubated with 2 µg of Ubc9 (Figs. 2E, 3C, 4D) or 2 µg of Smt3/4xSmt3 (Fig. 2F) in 30 µL of T buffer (25 mM Tris-Cl at pH 7.4, 10% glycerol, 0.5 mM EDTA, 0.01% Igepal, 1 mM DTT) supplemented

with 80 mM KCl for 30 min at 4°C. The protein mixture was incubated with 10 μ L of Glutathione Sepharose 4B resin (GE Healthcare) for 30 min at 4°C. After washing the resin four times with 200 μ L of T buffer with 80 mM KCl, bound proteins were eluted with 20 μ L of 2% SDS. For pull-down tests shown in Supplemental Figure S2C (lanes 1–6), 0.5 μ g of FLAG-Sgs1, 0.5 μ g of V5-Top3/GST-Rmi1, and 1.0 μ g of GST-Esc2 were incubated in 30 μ L T buffer with 80 mM KCl for 30 min at 4°C. The mixture was further incubated with 10 μ L of anti-FLAG agarose resin (Sigma) for 30 min at 4°C. After washing the resin four times with 200 μ L of the same buffer, bound proteins were eluted with 20 μ L of 2% SDS. For Strep-Tactin pull-down assays shown in Supplemental Figure S2C (lanes 7–12), 0.5 μ g of Myc-Smc5/(His)9-StreptagII-Smc6 complex and 1.0 μ g of GST-Esc2 were incubated in 30 μ L of T buffer with 80 mM KCl for 30 min at 4°C. The mixture was incubated with 10 μ L of Strep-Tactin resin that retains StreptagII-Smc6 for 30 min at 4°C. After washing the resin four times with 200 μ L of the same buffer, bound proteins were eluted with 20 μ L of 2% SDS. For GST pull-down assays shown in Supplemental Figure S5A, 3 μ g of GST-tagged Esc2 or its variants was incubated with 1.6 μ g of the Mus81-Mms4 complex in 30 μ L of T buffer supplemented with 100 mM KCl for 30 min at 4°C. The protein mixture was incubated with 10 μ L of Glutathione Sepharose 4B resin (GE Healthcare) for 30 min at 4°C. After washing the resin four times with 200 μ L of T buffer with 100 mM KCl, bound proteins were eluted with 20 μ L of 2% SDS. In all cases, 10% of the supernatant (S) and eluate (E) fractions and 2% of the wash (W) fraction were analyzed by SDS-PAGE and/or immunoblotted using anti-GST antibody (Sigma) (Supplemental Fig. S2C) or anti-His6 antibody (Sigma) (Supplemental Fig. S5A).

In vitro sumoylation assays

The *in vitro* sumoylation assay of the Sgs1-Top3-Rmi1 complex shown in Figure 4A was carried out by first incubating 20 nM STR complex with 2.2 μ M Smt3 (or Smt3-D68R), 50 nM Aosl-Uba2 (E1), and 280 nM Ubc9 (E2), with or without 40 nM Mms21/Smc5 complex (E3) in buffer R containing 45 mM Hepes-Na (pH 7.0), 5 mM MgCl₂, 72 mM KCl, and 0.1 mM DTT for 10 min on ice. The sumoylation reaction, upon the addition of 5 mM ATP, was shifted to 30°C. Samples were taken at indicated time points and mixed with sample loading buffer. Sumoylation reactions shown in Figure 4, B and E, were supplemented with or without 300 nM wild-type or mutant Esc2 in buffer R for 10 min on ice before adding ATP. In all cases, samples were taken at different time points to mix with sample buffer. Samples were analyzed by SDS-PAGE and immunoblotting using antibodies recognizing the tags on Sgs1 and Top3, including anti-FLAG (Sigma), anti-CBP (Genscript), or anti-V5 (Rockland).

A free SUMO chain formation assay (Supplemental Fig. S4D) was performed as above except omitting STR and the SUMO E3 in the reactions. Ubc9 thioester formation assay (Supplemental Fig. S4C) was performed as previously described (Knipscheer et al. 2007). In brief, 2.2 μ M Smt3 (or Smt3-D68R) was incubated with 50 nM Aosl-Uba2, 280 nM Ubc9, with or without 300 nM Esc2 in buffer R for 10 min on ice. The reaction, upon the addition of 5 mM ATP, was incubated at 30°C for the indicated time. Samples were mixed with nonreducing (without DTT) or reducing (with 50 mM DTT) loading buffer, analyzed by SDS-PAGE, and immunoblotted using an anti-Ubc9 antibody (Santa Cruz Biotechnology).

2D agarose gel electrophoresis

2D gel analysis was performed as previously described (Meng et al. 2020). Briefly, log-phase yeast cultures were treated with

5 μ g/mL a factor (Bio Basic) until at least 90% of cells exhibited G1 arrest. Cells were released from arrest by pronase treatment (Millipore), and MMS was added to a final concentration 0.03% for 2 h. Cells were collected and treated with zymolyase to produce spheroplasts. After cell lysis, proteinase K (Sigma-Aldrich) was added and DNA was purified by CsCl gradient centrifugation and precipitated. Extracted DNA was digested by EcoRI and separated by agarose gel electrophoresis in two dimensions. Separated DNA was transferred onto Hybond-XL membranes (GE Healthcare) and analyzed by Southern blotting using probes hybridizing to the ARS315 or ARS1212 locus. Primers used for probe amplification are listed in Supplemental Table S3. For quantification, the signals of 1N DNA were obtained from short exposures and X-mol signals from longer exposure. Signal levels fell within the linear range of detection for the PhosphorImager.

GCR assay

GCR rate measurement was performed as described previously (Meng et al. 2019). At least nine cultures were examined for each genotype. Cells were washed and serial dilutions were plated on synthetic complete (SC) medium and FC medium containing canavanine and 5-FOA. GCR rates were calculated as m/NT using the following formula: $m \times (1.24 + \ln[m]) - \text{NFC} = 0$, where m is mutational events, NFC is the number of colonies on FC plates, and NT is the number of colonies on SC plates. The upper and lower 95% confidence intervals (95% CI) were calculated as described (Putnam and Kolodner 2010). A two-tailed Mann-Whitney test was performed as described previously (Myung et al. 2004) using GraphPad Prism version 7.

Microscale thermophoresis (MST) analyses

His-tagged Ubc9 was labeled with a His-Tag labeling kit RED-tris-NTA (NT-L118, NanoTemper Technologies). The labeling reaction was performed according to the manufacturer's instructions. Twelve doses of Ubc9-His from 4 μ M–0.0039 μ M were prepared by 1:1 serial dilution using MST buffer, which contains 20 mM HEPES (pH 7.5), 80 mM KCl, 0.01% Igpal, and 1% glycerol. Each dose of Ubc9-His in 10 μ L of MST buffer was mixed with 40 nM Red-tris-NTA in 10 μ L of MST buffer for 30 min at room temperature in the dark. The mixture was loaded into premium Monolith NT.115 Capillaries (NanoTemper Technologies, MO-AK005) for binding affinity assay. MST was measured using a Monolith NT.115 instrument (NanoTemper Technologies) at 25°C. Instrument parameters were adjusted to 70% excitation power and medium MST power. Data was analyzed by MO.Affinity Analysis software (version 2.1.3, NanoTemper Technologies) using the signal from an MST-on time of 5 sec. The K_d of Ubc9-His labeling was 4 nM. To test the binding affinity of Ubc9 with Esc2, 40 nM Red-tris-NTA in 300 μ L of MST buffer was mixed with 80 nM of Ubc9-His in 300 μ L of MST buffer at room temperature for 30 min in the dark for labeling. After centrifugation at 15,000g for 10 min, the supernatant was transferred to a fresh tube for the binding assay with Esc2. A total of 16 concentrations of Esc2 were serially diluted using an equal volume of MST buffer from 20 μ M to 0.6 nM. Ten microliters of each dose of Esc2 was mixed with 10 μ L of His-labeled Ubc9 supernatant. The mixture of Ubc9 and Esc2 was loaded into premium capillaries for MST assay with parameters set up at 80% excitation power and medium MST power. Binding affinity was analyzed by the MO.Affinity Analysis software using the signal from an MST-on time of 2.5 sec. Three individual experiments were used to calculate the standard deviation.

Circular dichroism (CD) analyses

Purified Esc2 and Esc2-SLD2m proteins were diluted to 2.9 μ M in 300 μ L of CD buffer (10 mM NaH_2PO_4 , 100 mM KCl at pH 7.0). Spectra were collected by a Jasco J-710 spectropolarimeter at 20°C.

Acknowledgments

We thank Dana Branzei, Lumir Krejci, and Mark Hochstrasser for sharing yeast strains; Steve Brill, Helle Ulrich, and Hirano Araki for sharing antibodies; Weibin Wang for sharing the Top3-Rmi1 complex; Nicolas Paquet for sharing the Mus81-Mms4 complex; Koyi Choi for her early work on Esc2; and Prabha Sarangi for comments on the manuscript. We are grateful for the support of Patrick Sung, in whose laboratory in vitro work was initiated; Dirk Remus, who shared the strains for expressing the CBP-Top3 and Rmi1 complex; and Steven Whitten who helped in CD analyses. We acknowledge Dr. Matthew J. Hart and Dr. Daifeng Jiang for the MST analyses, funded in part by the University of Texas Health Science Center at San Antonio Greehey Children's Cancer Research Institute RNAi High-Throughput Screening Facility, Cancer Prevention and Research Institute of Texas grant RP160844, and Mays Cancer Center National Institutes of Health grant CA054174. This work is supported by the National Institutes of Health grants R21 ES028792 and R15 GM139135 and startup funds from Texas State University to X.X., and National Institute of General Medical Science grants GM080670 and GM131058 to X.Z.

Author contributions: S.L., J.N.B., X.X., and X.Z. designed experiments. S.L. and J.N.B. performed in vivo experiments, and X.X., S.S., A.S., and L.G. performed in vitro tests. B.W. generated structural models and purified sumoylation enzymes for in vitro tests. S.L., X.X., and X.Z. wrote the manuscript with editing by J.N.B.

References

- Albuquerque CP, Wang G, Lee NS, Kolodner RD, Putnam CD, Zhou H. 2013. Distinct SUMO ligases cooperate with Esc2 and Slx5 to suppress duplication-mediated genome rearrangements. *PLoS Genet* **9**: e1003670. doi:10.1371/journal.pgen.1003670
- Albuquerque CP, Liang J, Gaut NJ, Zhou H. 2016. Molecular circuitry of the SUMO (small ubiquitin-like modifier) pathway in controlling sumoylation homeostasis and suppressing genome rearrangements. *J Biol Chem* **291**: 8825–8835. doi:10.1074/jbc.M116.716399
- Bermúdez-López M, Villoria MT, Esteras M, Jarmuz A, Torres-Rosell J, Clemente-Blanco A, Aragon L. 2016. Sgs1's roles in DNA end resection, HJ dissolution, and crossover suppression require a two-step SUMO regulation dependent on Smc5/6. *Genes Dev* **30**: 1339–1356. doi:10.1101/gad.278275.116
- Bonner JN, Choi K, Xue X, Torres NP, Szakal B, Wei L, Wan B, Arter M, Matos J, Sung P, et al. 2016. Smc5/6 mediated sumoylation of the Sgs1-Top3-Rmi1 complex promotes removal of recombination intermediates. *Cell Rep* **16**: 368–378. doi:10.1016/j.celrep.2016.06.015
- Branzei D, Sollier J, Liberi G, Zhao X, Maeda D, Seki M, Enomoto T, Ohta K, Foiani M. 2006. Ubc9- and Mms21-mediated sumoylation counteracts recombinogenic events at damaged replication forks. *Cell* **127**: 509–522. doi:10.1016/j.cell.2006.08.050
- Choi K, Szakal B, Chen YH, Branzei D, Zhao X. 2010. The Smc5/6 complex and Esc2 influence multiple replication-associated recombination processes in *Saccharomyces cerevisiae*. *Mol Biol Cell* **21**: 2306–2314. doi:10.1091/mbc.e10-01-0050
- Chung I, Zhao X. 2015. DNA break-induced sumoylation is enabled by collaboration between a SUMO ligase and the ssDNA-binding complex RPA. *Genes Dev* **29**: 1593–1598. doi:10.1101/gad.265058.115
- Cremona CA, Sarangi P, Yang Y, Hang LE, Rahman S, Zhao X. 2012. Extensive DNA damage-induced sumoylation contributes to replication and repair and acts in addition to the Mec1 checkpoint. *Mol Cell* **45**: 422–432. doi:10.1016/j.molcel.2011.11.028
- Devbhandari S, Jiang J, Kumar C, Whitehouse I, Remus D. 2017. Chromatin constrains the initiation and elongation of DNA replication. *Mol Cell* **65**: 131–141. doi:10.1016/j.molcel.2016.10.035
- Dhingra N, Wei L, Zhao X. 2019. Replication protein A (RPA) sumoylation positively influences the DNA damage checkpoint response in yeast. *J Biol Chem* **294**: 2690–2699. doi:10.1074/jbc.RA118.006006
- Duan X, Sarangi P, Liu X, Rangi GK, Zhao X, Ye H. 2009. Structural and functional insights into the roles of the Mms21 subunit of the Smc5/6 complex. *Mol Cell* **35**: 657–668. doi:10.1016/j.molcel.2009.06.032
- Duda DM, van Waardenburg RC, Borg LA, McGarity S, Nourse A, Waddell MB, Bjornsti MA, Schulman BA. 2007. Structure of a SUMO-binding-motif mimic bound to Smt3p-Ubc9p: conservation of a non-covalent ubiquitin-like protein-E2 complex as a platform for selective interactions within a SUMO pathway. *J Mol Biol* **369**: 619–630. doi:10.1016/j.jmb.2007.04.007
- Gillies J, Hickey CM, Su D, Wu Z, Peng J, Hochstrasser M. 2016. SUMO pathway modulation of regulatory protein binding at the ribosomal DNA locus in *Saccharomyces cerevisiae*. *Genetics* **202**: 1377–1394. doi:10.1534/genetics.116.187252
- Hoeghe C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S. 2002. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. *Nature* **419**: 135–141. doi:10.1038/nature00991
- Hurov KE, Cotta-Ramusino C, Elledge SJ. 2010. A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability. *Genes Dev* **24**: 1939–1950. doi:10.1101/gad.1934210
- Kanellis P, Gagliardi M, Banath JP, Szilard RK, Nakada S, Galicia S, Sweeney FD, Cabelof DC, Olive PL, Durocher D. 2007. A screen for suppressors of gross chromosomal rearrangements identifies a conserved role for PLP in preventing DNA lesions. *PLoS Genet* **3**: e134. doi:10.1371/journal.pgen.0030134
- Knipscheer P, van Dijk WJ, Olsen JV, Mann M, Sixma TK. 2007. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation. *EMBO J* **26**: 2797–2807. doi:10.1038/sj.emboj.7601711
- Knipscheer P, Flotho A, Klug H, Olsen JV, van Dijk WJ, Fish A, Johnson ES, Mann M, Sixma TK, Pichler A. 2008. Ubc9 sumoylation regulates SUMO target discrimination. *Mol Cell* **31**: 371–382. doi:10.1016/j.molcel.2008.05.022
- Liberi G, Maffioletti G, Lucca C, Chiolo I, Baryshnikova A, Cotta-Ramusino C, Lopes M, Pelliccioli A, Haber JE, Foiani M. 2005. Rad51-dependent DNA structures accumulate at damaged replication forks in *sgs1* mutants defective in the yeast ortholog of BLM RecQ helicase. *Genes Dev* **19**: 339–350. doi:10.1101/gad.322605
- Lindroos HB, Ström L, Itoh T, Katou Y, Shirahige K, Sjögren C. 2006. Chromosomal association of the Smc5/6 complex

- reveals that it functions in differently regulated pathways. *Mol Cell* **22**: 755–767. doi:10.1016/j.molcel.2006.05.014
- Mankouri HW, Ngo HP, Hickson ID. 2009. Esc2 and Sgs1 act in functionally distinct branches of the homologous recombination repair pathway in *Saccharomyces cerevisiae*. *Mol Biol Cell* **20**: 1683–1694. doi:10.1091/mbc.e08-08-0877
- Matos J, Blanco MG, Maslen S, Skehel JM, West SC. 2011. Regulatory control of the resolution of DNA recombination intermediates during meiosis and mitosis. *Cell* **147**: 158–172. doi:10.1016/j.cell.2011.08.032
- Matulova P, Marini V, Burgess RC, Sisakova A, Kwon Y, Rothstein R, Sung P, Krejci L. 2009. Cooperativity of Mus81.Mms4 with Rad54 in the resolution of recombination and replication intermediates. *J Biol Chem* **284**: 7733–7745. doi:10.1074/jbc.M806192200
- Meng X, Wei L, Peng XP, Zhao X. 2019. Sumoylation of the DNA polymerase ϵ by the Smc5/6 complex contributes to DNA replication. *PLoS Genet* **15**: e1008426. doi:10.1371/journal.pgen.1008426
- Meng X, Wei L, Devbhandari S, Zhang T, Xiang J, Remus D, Zhao X. 2020. DNA polymerase ϵ relies on a unique domain for efficient replisome assembly and strand synthesis. *Nat Commun* **11**: 2437. doi:10.1038/s41467-020-16095-x
- Myung K, Smith S, Kolodner RD. 2004. Mitotic checkpoint function in the formation of gross chromosomal rearrangements in *Saccharomyces cerevisiae*. *Proc Natl Acad Sci* **101**: 15980–15985. doi:10.1073/pnas.0407010101
- Niu H, Chung WH, Zhu Z, Kwon Y, Zhao W, Chi P, Prakash R, Seong C, Liu D, Lu L, et al. 2010. Mechanism of the ATP-dependent DNA end-resection machinery from *Saccharomyces cerevisiae*. *Nature* **467**: 108–111. doi:10.1038/nature09318
- Novatchkova M, Bachmair A, Eisenhaber B, Eisenhaber F. 2005. Proteins with two SUMO-like domains in chromatin-associated complexes: the RENi (Rad60-Esc2-NIP45) family. *BMC Bioinformatics* **6**: 22. doi:10.1186/1471-2105-6-22
- Pichler A, Fatouros C, Lee H, Eisenhardt N. 2017. SUMO conjugation—a mechanistic view. *Biomol Concepts* **8**: 13–36. doi:10.1515/bmc-2016-0030
- Prudden J, Perry JJ, Arvai AS, Tainer JA, Boddy MN. 2009. Molecular mimicry of SUMO promotes DNA repair. *Nat Struct Mol Biol* **16**: 509–516. doi:10.1038/nsmb.1582
- Prudden J, Perry JJ, Nie M, Vashisht AA, Arvai AS, Hitomi C, Guenther G, Wohlschlegel JA, Tainer JA, Boddy MN. 2011. DNA repair and global sumoylation are regulated by distinct Ubc9 noncovalent complexes. *Mol Cell Biol* **31**: 2299–2310. doi:10.1128/MCB.05188-11
- Psakhye I, Jentsch S. 2012. Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair. *Cell* **151**: 807–820. doi:10.1016/j.cell.2012.10.021
- Putnam CD, Kolodner RD. 2010. Determination of gross chromosomal rearrangement rates. *Cold Spring Harb Protoc* **2010**: pdb.prot5492. doi:10.1101/pdb.prot5492
- Putnam CD, Hayes TK, Kolodner RD. 2009. Specific pathways prevent duplication-mediated genome rearrangements. *Nature* **460**: 984–989. doi:10.1038/nature08217
- Raffa GD, Wohlschlegel J, Yates JR 3rd, Boddy MN. 2006. SUMO-binding motifs mediate the Rad60-dependent response to replicative stress and self-association. *J Biol Chem* **281**: 27973–27981. doi:10.1074/jbc.M601943200
- Sarangi P, Altmannova V, Holland C, Bartosova Z, Hao F, Arranther D, Ammerer G, Lee SE, Krejci L, Zhao X. 2014. A versatile scaffold contributes to damage survival via sumoylation and nuclease interactions. *Cell Rep* **9**: 143–152. doi:10.1016/j.celrep.2014.08.054
- Sebesta M, Urulangodi M, Stefanovie B, Szakal B, Pacesa M, Lisby M, Branzei D, Krejci L. 2017. Esc2 promotes Mus81 complex-activity via its SUMO-like and DNA binding domains. *Nucleic Acids Res* **45**: 215–230. doi:10.1093/nar/gkw882
- Sekiya N, Arita K, Ikeda Y, Hashiguchi K, Ariyoshi M, Tochio H, Saitoh H, Shirakawa M. 2010. Structural basis for regulation of poly-SUMO chain by a SUMO-like domain of Nip45. *Proteins* **78**: 1491–1502. doi:10.1002/prot.22667
- Sollier J, Driscoll R, Castellucci F, Foiani M, Jackson SP, Branzei D. 2009. The *Saccharomyces cerevisiae* Esc2 and Smc5-6 proteins promote sister chromatid junction-mediated intra-S repair. *Mol Biol Cell* **20**: 1671–1682. doi:10.1091/mbc.e08-08-0875
- Stelter P, Ulrich HD. 2003. Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation. *Nature* **425**: 188–191. doi:10.1038/nature01965
- Streich FC Jr, Lima CD. 2016. Capturing a substrate in an activated RING E3/E2-SUMO complex. *Nature* **536**: 304–308. doi:10.1038/nature19071
- Takahashi Y, Dulev S, Liu X, Hiller NJ, Zhao X, Strunnikov A. 2008. Cooperation of sumoylated chromosomal proteins in rDNA maintenance. *PLoS Genet* **4**: e1000215. doi:10.1371/journal.pgen.1000215
- Talhaoui I, Bernal M, Mullen JR, Dorison H, Palancade B, Brill SJ, Mazón G. 2018. Slx5-Slx8 ubiquitin ligase targets active pools of the Yen1 nuclease to limit crossover formation. *Nat Commun* **9**: 5016. doi:10.1038/s41467-018-07364-x
- Ulrich HD, Davies AA. 2009. *In vivo* detection and characterization of sumoylation targets in *Saccharomyces cerevisiae*. *Methods Mol Biol* **497**: 81–103. doi:10.1007/978-1-59745-566-4_6
- Urulangodi M, Sebesta M, Menolfi D, Szakal B, Sollier J, Sisakova A, Krejci L, Branzei D. 2015. Local regulation of the Srs2 helicase by the SUMO-like domain protein Esc2 promotes recombination at sites of stalled replication. *Genes Dev* **29**: 2067–2080. doi:10.1101/gad.265629.115
- Wang W, Daley JM, Kwon Y, Xue X, Krasner DS, Miller AS, Nguyen KA, Williamson EA, Shim EY, Lee SE, et al. 2018. A DNA nick at Ku-blocked double-strand break ends serves as an entry site for exonuclease 1 (Exo1) or Sgs1-Dna2 in long-range DNA end resection. *J Biol Chem* **293**: 17061–17069. doi:10.1074/jbc.RA118.004769
- Wei L, Zhao X. 2016. A new MCM modification cycle regulates DNA replication initiation. *Nat Struct Mol Biol* **23**: 209–216. doi:10.1038/nsmb.3173
- Whalen JM, Dhingra N, Wei L, Zhao X, Freudenreich CH. 2020. Relocation of collapsed forks to the nuclear pore complex depends on sumoylation of DNA repair proteins and permits Rad51 association. *Cell Rep* **31**: 107635. doi:10.1016/j.celrep.2020.107635
- Winczura A, Appanah R, Tatham MH, Hay RT, De Piccoli G. 2019. The S phase checkpoint promotes the Smc5/6 complex dependent SUMOylation of Pol2, the catalytic subunit of DNA polymerase ϵ . *PLoS Genet* **15**: e1008427. doi:10.1371/journal.pgen.1008427
- Xue X, Choi K, Bonner J, Chiba T, Kwon Y, Xu Y, Sanchez H, Wyman C, Niu H, Zhao X, et al. 2014. Restriction of replication fork regression activities by a conserved SMC complex. *Mol Cell* **56**: 436–445. doi:10.1016/j.molcel.2014.09.013
- Zhao X, Blobel G. 2005. A SUMO ligase is part of a nuclear multiprotein complex that affects DNA repair and chromosomal organization. *Proc Natl Acad Sci* **102**: 4777–4782. doi:10.1073/pnas.0500537102

Li_Supplemental Fig1




Figure S1. *esc2Δ* cells maintain sumoylation levels of Siz E3 substrates.

(A) Sumoylation of the HJ resolution enzyme Yen1 is not altered in *esc2Δ* cells.

(B) Sumoylation of PCNA a replication fork associated protein, is not reduced by *esc2Δ*.

(C) Sumoylation of Saw1, which binds to DNA flap structures, is not reduced by *esc2Δ*.

Experiments were performed and data are represented as Figure1A (for panel A-B) or Figure1B left (for panel C).




Figure S2. Examination of Esc2 interactions with Sgs1-Top3-Rmi1, Smc5/6 and Pol2.

(A) Immunoblots showing that Pol2 is co-purified with Dpb2 but not with Esc2. Experiments were performed and data are represented as Figure 2A.

(B) Purified proteins used in the *in vitro* studies. Esc2, Sgs1, the Top3-Rmi1 complex, the Smc5-Smc6 complex, Ubc9, SUMO, 4X-SUMO proteins were purified and analyzed by SDS-PAGE. Pictures of Coomassie blue stained gels are shown.

(C) Examination of Esc2 interactions with the Sgs1-Top3-Rmi1 complex and the Smc5-Smc6 complex *in vitro*. Affinity pull-down results for the Sgs1-Flag fusion protein (Lane 1-6, using anti-Flag beads) and for the Smc5-Strep-Tactin fusion protein (Lanes 7-12, using Strep-Tactin beads) are shown. Indicated fractions from the pull-down experiments were examined by immunoblotting using anti-GST antibody. Note that GST-Esc2 showed non-specific binding to both types of beads in the eluted fraction.

(D) Smc5 immuno-precipitated Pol2 at similar levels in WT and *esc2Δ* cells. Experiments were performed and data are represented as Figure 2D.

(E) MST measurement of the Esc2 interaction with Ubc9. Error bars represent standard deviations calculated from three independent thermophoresis measurements.

Li_Supplemental Fig3




Figure S3. Assays to assess *in vitro* sumoylation of Sgs1.

(A) SLD2 adopts a similar fold as SUMO and both bind to the Ubc9 backside. Left, superimposition of the structure of the SUMO-Ubc9 complex from *Saccharomyces cerevisiae* (Sc; PDB: 2EKE) and that of the SLD2-Ubc9 complex from *Schizosaccharomyces pombe* (Sp; PDB 3RCZ). The Ubc9 active site Cys93 is marked. Right, cartoon to show that SUMO or SLD2 binds noncovalently to the Ubc9 (E2) backside, while the SUMO moiety (S, yellow) to be transferred to substrates is covalently conjugated at the Ubc9 active site.

(B) A structural model of the complex composed of ScUbc9 and the SLD2 of Esc2. The structure of Esc2's SLD2 was modeled based on that of the SLD2 of Rad60 (PDB:3RCZ). This model and the structure of the budding yeast Ubc9 (PDB:2EKE) were used to generate the complex model based on the structure of the complex of SpUbc9 and the SLD2 of Rad60 (PDB: 3RCZ). A close-up view highlights that D449 of SLD2 forms two salt bridges (dashed lines) with Arg17 of Ubc9. SWISS-MODEL was used to generate the models.

(C, F) Purified proteins used in our *in vitro* studies. Indicated proteins were purified and analyzed by SDS-PAGE. Pictures of Coomassie blue stained gels are shown.

(D) CD profiles of the wild-type Esc2 protein and the Esc2-SLD2m mutant protein.

(E) Esc2-SLD2m, but not Esc2-SLD1m, maintains wild-type protein levels. Protein extracts from cells with indicated genotype were examined by immunoblotting. Quantification of protein levels was graphed. Student T-test was used for statistical analyses and error bars indicate standard deviations. ns: not statistically significant.

(G) *In vitro* sumoylation of Sgs1 requires its SIMs (SUMO interacting motifs) and the main sumoylation site K621. *In vitro* sumoylation assays were performed by incubating purified Sgs1 or its variants with the SUMO E1, the SUMO E2, Smt3, and ATP at 30 °C for 60 minutes. Sgs1 variants include point mutations at its SIMs (sim) and at its main sumoylation site K621 (K621R) (Bonner et al. 2016). Unmodified Sgs1 or its variants (blue dots) and their sumoylated forms (blue lines) were detected by immunoblotting against the Flag tag fused to Sgs1. The same blot probed with the anti-SUMO antibody showed that Sgs1-sim and Sgs1-K621R only affected the sumoylation of higher molecular weight species corresponding to Sgs1. The lower molecular weight species, likely representing sumoylation of the SUMO E1, are not affected by Sgs1-sim or Sgs1-K621R.

Li_Supplemental Fig4




Figure S4. The effects of SUMO-D68R and Esc2 in sumoylation reactions.

(A-B) SUMO but not SUMO-DR competes with Esc2 for Ubc9 binding. *In vitro* pull-down experiments were performed, and data are presented as in Figure 2E. Ubc9 could bind to GST-Esc2 (lane 8), but not to GST (lane 7). The addition of increased concentrations of SUMO (panel A), but not SUMO-DR (panel B), displaced Ubc9 from GST-Esc2 bound to the glutathione beads.

(C) SUMO-DR is proficient to charge Ubc9 *in vitro*. SUMO-WT or D68R was incubated with the SUMO E1, the SUMO E2, and ATP at 30 °C for the indicated time. Samples were analyzed by SDS-PAGE under non-reducing (-DTT) or reducing (+DTT) condition and probed by anti-Ubc9 antibody. As seen previously, this reaction generated charged SUMO E2 (SUMO^{thio}Ubc9) wherein SUMO is covalently linked to Ubc9, and this form is sensitive to DTT (Knipscheer et al. 2007). SUMO-DR behaved like SUMO in this reaction. Esc2 addition (Lane 9-12) did not affect SUMO-DR conjugation to Ubc9.

(D) Esc2 does not stimulate free SUMO chain formation. Sumoylation assays were performed by incubating the SUMO E1, the SUMO E2, SUMO (or SUMO-DR), ATP, with or without Esc2 at 30 °C for the indicated time. SUMO chains containing different numbers of SUMO moieties and sumoylated Ubc9 were detected by immunoblotting using an anti-SUMO antibody.




Figure S5. Esc2-SLD2m binds to Mus81-Mms4 and *esc2-SLD2Δ-SuDR*, but not *esc2-SLD2Δ-Su*, sensitizes *slx4Δ* and *mms4Δ* mutants.

(A) Esc2-SLD2m interacts with the Mus81-Mms4^{His6} complex *in vitro*. Top: GST pulldown tests were performed and results are presented as in Figure 2E. Note that the Mms4 protein runs at the same position as GST-Esc2 in gels. Bottom: Mms4 was detected by an anti-His₆ antibody in immunoblotting.

(B-C) *esc2-SLD2Δ-SuDR*, but not *esc2-SLD2Δ-Su*, worsens genotoxic sensitivity of *slx4Δ* and *mms4Δ* cells. Cells were spotted in 10-fold serial dilutions and grown at 30 °C for 2 days.

Table S1. Yeast strains used in this study

Name	Genotype	Source
X7559-8A	<i>SGS1-9myc::KAN 8His-SMT3::TRP1 ESC2-10FLAG::KAN</i>	This study
X7704-5A	<i>SGS1-9myc::KAN 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X7555-5B	<i>TOP3-TAP::HIS3 8His-SMT3::TRP1 ESC2-10FLAG::KAN</i>	This study
X7705-1C	<i>TOP3-TAP::HIS3 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X7556-13B	<i>RMI1-TAP::HIS3 8His-SMT3::TRP1 ESC2-10FLAG::KAN</i>	This study
X7706-11B	<i>RMI1-TAP::HIS3 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X7816-2A	<i>POL2-3HA::KAN ESC2-10FLAG::KAN</i>	This study
X8357-3B	<i>POL2-3HA::KAN esc2Δ::KAN</i>	This study
X8374-1C	<i>ADH-3HA-MCM3::NAT 8His-SMT3::TRP1</i>	This study
X8374-4A	<i>ADH-3HA-MCM3::NAT 8His-SMT3::TRP1; esc2Δ::KAN</i>	This study
T439-2	<i>YKU70-TAF::KAN</i>	Lab collection
X7710-5A	<i>YKU70-TAF::KAN esc2Δ::KAN</i>	This study
X4641-2A	<i>SMC5-TAP::TRP1 8His-SMT3::TRP1</i>	This study
X7501-5C	<i>SMC5-TAP::TRP1 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X8341-3B	<i>SMC6-13Myc::HIS3 8His-SMT3::TRP1</i>	This study
X8341-4A	<i>SMC6-13Myc::HIS3 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X7708-3A	<i>NSE4-13myc::HIS3 8His-SMT3::TRP1</i>	This study
X7708-3D	<i>NSE4-13myc::HIS3 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X7709-2C	<i>SMC1-TAP::HIS3 8His-SMT3::TRP1</i>	This study
X7709-2A	<i>SMC1-TAP::HIS3 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X7591-2A	<i>SMC3-TAP::HIS3 8His-SMT3::TRP1</i>	This study
X7591-8A	<i>SMC3-TAP::HIS3 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X8430-3D	<i>SMC2-3HA::KAN 8His-SMT3::TRP1</i>	This study
X8430-1C	<i>SMC2-3HA::KAN 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X7592-1C	<i>SMC4-myc::HIS3 8His-SMT3::TRP1</i>	This study
X7592-8D	<i>SMC4-myc::HIS3 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X5602-10C	<i>SGS1-3HA::LEU2 ESC2-13myc::KAN</i>	This study
X5602-7C	<i>SGS1-3HA::LEU2 ESC2-13myc::KAN SMC5-TAP::TRP1</i>	This study
X5766-8A	<i>SGS1-3HA::KAN</i>	This study
X5766-8B	<i>SGS1-3HA::KAN SMC5-TAP::TRP1</i>	This study
X5573-22A	<i>SGS1-3HA::LEU2 SMC5-TAP::TRP1 esc2Δ::KAN</i>	This study
X7561-1A	<i>SGS1-9myc::KAN 8His-SMT3::TRP1 esc2-SLD1m-10FLAG::KAN</i>	This study
X7562-5A	<i>SGS1-9myc::KAN 8His-SMT3::TRP1 esc2-SLD2m-10FLAG::KAN</i>	This study
X7551-4A	<i>TOP3-TAP::HIS3 8His-SMT3::TRP1 esc2-SLD1m-10FLAG::KAN</i>	This study
X7553-2C	<i>TOP3-TAP::HIS3 8His-SMT3::TRP1 esc2-SLD2m-10FLAG::KAN</i>	This study
X7557-3B	<i>RMI1-TAP::HIS3 8His-SMT3::TRP1 esc2-SLD1m-10FLAG::KAN</i>	This study
X7558-5C	<i>RMI1-TAP::HIS3 8His-SMT3::TRP1 esc2-SLD2m-10FLAG::KAN</i>	This study
X8356-14C	<i>POL2-3HA::KAN esc2-SLD1m-10FLAG::KAN</i>	This study
X7566-1D	<i>POL2-3HA::KAN esc2-SLD2m-10FLAG::KAN</i>	This study
X8439-1C	<i>ADH-3HA-MCM3-HA::NAT 8His-SMT3::TRP1 esc2-SLD1m::KAN</i>	This study

X8440-4A	<i>ADH-3HA-MCM3-HA::NAT 8His-SMT3::TRP1 esc2-SLD2m-10FLAG::KAN</i>	This study
X8393-16C	<i>SGS1-9myc::KAN 8His-SMT3::TRP1 ESC2-SLD2A-SUMO-10FLAG::KAN</i>	This study
X8433-2-13C	<i>SGS1-9myc::KAN 8His-SMT3::TRP1 ESC2-SLD2A-SUMO-D68R-10FLAG::KAN</i>	This study
X8409-13A	<i>TOP3-TAP::HIS3 8His-SMT3::TRP1 ESC2-SLD2A-SUMO-10FLAG::KAN</i>	This study
X8435-7B	<i>TOP3-TAP::HIS3 8His-SMT3::TRP1 ESC2-SLD2A-SUMO-D68R-10FLAG::KAN</i>	This study
X8394-6A	<i>RM11-TAP::HIS3 8His-SMT3::TRP1 ESC2-SLD2A-SUMO-10FLAG::KAN</i>	This study
X8434-3A	<i>RM11-TAP::HIS3 8His-SMT3::TRP1 ESC2-SLD2A-SUMO-D68R-10FLAG::KAN</i>	This study
X8021-2-2C	<i>mms4Δ::KAN</i>	This study
X8021-2-2D	<i>esc2-SLD2m-10FLAG::KAN</i>	This study
X8021-2-2B	<i>mms4Δ::KAN esc2-SLD2m-10FLAG::KAN</i>	This study
X8009-9D	<i>slx4Δ::NAT</i>	This study
X8009-9B	<i>slx4Δ::NAT esc2-SLD2m-10FLAG::KAN</i>	This study
X7768-2C	<i>YEN1-TAP::HIS3 8His-SMT3::TRP1</i>	This study
X7768-14D	<i>YEN1-TAP::HIS3 8His-SMT3::TRP1 esc2Δ::KAN</i>	This study
X7549-10B	<i>SAW1-TAP::HIS3</i>	This study
X7549-3C	<i>SAW1-TAP::HIS3 esc2Δ::KAN</i>	This study
X7556-9D	<i>ESC2-10FLAG::KAN</i>	This study
X7816-2A	<i>ESC2-10FLAG::KAN POL2-3HA::KAN</i>	This study
X3598-15d	<i>SMC5-myc::HIS3 POL2-3HA::KAN</i>	Lab collection
X8275-1B	<i>SMC5-myc::HIS3 POL2-3HA::KAN esc2Δ::KAN</i>	This study
X5706-5-11D	<i>SMC5-myc::HIS3</i>	This study
X8424-2-13B	<i>ESC2-SLD2A-SUMO-10FLAG::KAN</i>	This study
X8424-2-13C	<i>mms4Δ::KAN ESC2-SLD2A-SUMO-10FLAG::KAN</i>	This study
X8470-13A	<i>ESC2-SLD2A-SUMO-D68R-10FLAG::KAN</i>	This study
X8470-13B	<i>mms4Δ::KAN ESC2-SLD2A-SUMO-D68R-10FLAG::KAN</i>	This study
X8471-14A	<i>slx4Δ::NAT ESC2-SLD2A-SUMO-10FLAG::KAN</i>	This study
X8472-14B	<i>slx4Δ::NAT ESC2-SLD2A-SUMO-D68R-10FLAG::KAN</i>	This study

Table S2. Plasmids used in this study.

Name	Vector information	Source
	pOAD	lab collection
pXZ170	pOAD-Nse1	lab collection
pXZ89	pOAD-Mms21	lab collection
p2	pOAD-Nse3	lab collection
pXZ212	pOAD-Nse4	lab collection
pXZ188	pOAD-Nse5	lab collection
pXZ166	pOAD-Nse6	lab collection
pXZ189	pOAD-Smc5	lab collection
pXZ171	pOAD-Smc6	lab collection
pXZ217	pOAD-Sgs1	lab collection
pXZ549	pOAD-Top3	lab collection
pXZ558	pOAD-Rmi1	lab collection

pXZ93	pOAD-Ubc9	lab collection
pXZ220	pOAD-Smt3	lab collection
	pOBD	lab collection
pXZ434	pOBD-Esc2	lab collection
pXZ890	pOBD-Esc2-SLD1m	This study
pXZ891	pOBD-Esc2-SLD2m	This study
	pGEX-6P-Esc2	(Sebesta et al. 2017)
	pGEX-6P-Esc2-SLD2m	This study
	pGEX-6P-Esc2-SLD2Δ-Su	This study
	pGEX-6P-Esc2-SLD2Δ-SuDR	This study
	pFastBac-HTB-Flag-Sgs1	(Niu et al. 2010)
pLK79	pET11c-V5-Top3	(Niu et al. 2010)
	pGEX-6P-Rmi1	(Niu et al. 2010)
pXZ114	pET15b-Mms21	(Duan et al. 2009)
pXZ115	pET28a-Smc5	(Duan et al. 2009)
p588	pET28a-4xSmt3	(Gillies et al. 2016)
	pESC-Trp-Myc-Smc5	(Niu et al. 2010)
	2μ-His ₉ -Strep-Tactin-Smc6	(Niu et al. 2010)
pXZ998	pRSFDuet-GST-Aos1	(Zhao and Blobel 2005)
pXZ999	pET22-Uba2	(Zhao and Blobel 2005)
p541	pET21a-Smt3	lab collection
pXZ893	pET21a-Smt3-D68R	This study
G1827	pET-Ubc9	lab collection

Table S3. Primers used in this study.

Name	Sequence (5'- -> 3')
ARS315-Forward	GTGCTGCAAAGGCCATGAAA
ARS315-Reverse	ACATGAACTGTATGCCCCGCA
ARS1212-Forward	AGTTTCGGGTTTCAGAGGCAG
ARS1212-Reverse	GTCTTCACCAGCTTGGGGTT